Share Twitter LinkedIn Facebook Email Josep Piulats, M.D., PhD, Catalan Cancer Institute discusses TRITON2 Trial, Rucaparib PARP Inhibitor Data. At ESMO Oncology Conference – Munich, Germany On October 19, 2018.
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read
Pioneering Advances in Non-Metastatic Prostate Cancer: Navigating ARPIs and Precision Diagnostics for Tailored Treatment [39 SLIDES] Prostate 5 Mins Read
Promontory Therapeutics: PT-112 triggers organelle stress and ribosomal inhibition Prostate 2 Mins Read
